| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Inkblottherapy.com offers affordable, secure video counselling any time, any place. We are on a mission to increase accessibility to high quality mental health counselling in Canada.
Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores
SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Taylst is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.